Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Avastin off-licence

Bayer symbol

Bayer helps bankroll new stem cell company BlueRock

Start-up receives $225m to develop cardiovascular and neurodegenerative disease therapies

- PMLiVE

Novartis’ AMD drug pegpleranib fails phase III programme

Plans for Lucentis-boosting duel-therapy stumble as trial data show no additional benefit

- PMLiVE

InterComm International under new management

Malcolm Allison and Ben Greeves take over the med comms agency

- PMLiVE

NICE changes stance on GSK’s asthma drug Nucala

A newly-agreed price cut and additional cost-effectiveness data prompt U-turn

- PMLiVE

Bayer wins Company of the Year at PMEA 2016

Sees off strong competition from AbbVie, Celgene and Novartis

- PMLiVE

Hey You! campaign targets over 60s at high risk of stroke

Bayer launches atrial fibrillation awareness drive starring rock and roll

- PMLiVE

Pfizer to shut down two UK manufacturing sites

Over 370 jobs at the north London and Hampshire plants are at risk

EU flag

Pfizer’s first-in-class breast cancer therapy wins EU licence

Ibrance given the green light as a first-line treatment in Europe

Artificial intelligence firm licenses Janssen candidates for development

UK-based BenevolentAI aims to move them into late-stage trials by mid-2017

National Institute for Health and Care Excellence NICE logo

NICE backs Novartis’ Afinitor and Pfizer’s Xalkori

Provisionally approves breast and lung cancer drugs after greater discounts offered

- PMLiVE

NICE set to knock-back Amgen’s myeloma treatment Kyprolis

Cites uncertainty in clinical and cost-effectiveness analyses

Bristol Myers Squibb logo

BMS wins early UK access for Opdivo in Hodgkin’s lymphoma

Cancer treatment approved by the MHRA for use before EU licence in place

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links